Case reportPublished 28 Feb 2022
Utilizing Liquid Biopsy for Treatment Management in Bone Dominant Metastatic Breast Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Applications of liquid biopsy are primarily to monitor treatment response and to detect secondary treatment resistant mutations. In patients with bone-dominant metastatic breast cancer it can be challenging to evaluate for new mutations. Here, we present two patient cases with bone-dominant hormone positive metastatic breast cancer in whom we utilized liquid biopsy testing to guide therapy upon disease progression. Liquid biopsies were used to evaluate circulating-tumor DNA and analyzed for mutations using next generation sequencing. PIK3CA mutations were identified in both cases allowing the use of FDA approved PIK3CA-directed treatment with alpelisib. These cases demonstrate the clinical use of liquid biopsy in identifying actionable mutations, offering patients targeted treatment options without undergoing a metastatic biopsy. More real world reports are needed to further understand current liquid biopsy utilization in oncology patient care.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Oncology: Case Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Shirley Cheng”
- BylineArticles whose byline prints “Edward Nguyen”
- BylineArticles whose byline prints “Jami Fukui”
